{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:10:44Z","timestamp":1789755044883,"version":"4.0.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cellsig.2026.112885","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:45:49Z","timestamp":1789195549000},"page":"112885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Metabolic plasticity in castration-resistant prostate cancer: reprogramming mechanisms and therapeutic opportunities"],"prefix":"10.1016","volume":"149","author":[{"given":"Yanzhi","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengda","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2026.112885_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117829","article-title":"PSMA targeted therapy: from molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer","volume":"296","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.cellsig.2026.112885_bb0010","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-23-2260","article-title":"The critical interplay of CAF plasticity and resistance in prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.cellsig.2026.112885_bb0015","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1158\/0008-5472.CAN-23-2858","article-title":"Citron kinase is a druggable target in treatment-resistant prostate cancer","volume":"83","author":"Mishra","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12967-025-06322-8","article-title":"Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer","volume":"23","author":"Guo","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189333","article-title":"mRNA vaccines for prostate cancer: a novel promising immunotherapy","volume":"1880","author":"Tang","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112885_bb0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.semcancer.2020.12.002","article-title":"Metabolic regulation of prostate cancer heterogeneity and plasticity","volume":"82","author":"Peitzsch","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"24","key":"10.1016\/j.cellsig.2026.112885_bb0035","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1097\/CM9.0000000000003844","article-title":"Revisiting the role of metabolic reprogramming as a contributor to prostate cancer disease progression","volume":"138","author":"Ding","year":"2025","journal-title":"Chin. Med. J."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0040","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112885_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120476","article-title":"Propranolol promotes glucose dependence and synergizes with dichloroacetate for anti-cancer activity in HNSCC","volume":"10","author":"Lucido","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamaoncol.2017.3588","article-title":"Positron emission tomography\/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer","volume":"4","author":"Fox","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41419-025-08089-8","article-title":"PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer","volume":"16","author":"Chen","year":"2025","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0060","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/0008-5472.CAN-21-2988","article-title":"EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2\/c-Myc\/LDHA Signaling","volume":"82","author":"Jiang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112885_bb0065","article-title":"A glycolysis-related five-gene signature predicts biochemical recurrence-free survival in patients with prostate adenocarcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0070","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","article-title":"Metabolic plasticity and cancer stem cell metabolism: exploring the glycolysis-OXPHOS switch as a mechanism for resistance and tumorigenesis","volume":"21","author":"Keoh","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0075","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.124.002424","article-title":"Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer","volume":"392","author":"Simpson","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.cellsig.2026.112885_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26189132","article-title":"Reprogrammed lipid metabolism-associated therapeutic vulnerabilities in prostate cancer","volume":"26","author":"Parupathi","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer","volume":"116","author":"Zadra","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0090","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/1541-7786.MCR-18-0347","article-title":"Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer","volume":"17","author":"Balaban","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/0008-5472.CAN-23-0555","article-title":"Adipose triglyceride lipase is a therapeutic target in advanced prostate cancer that promotes metabolic plasticity","volume":"84","author":"Awad","year":"2024","journal-title":"Cancer Res."},{"issue":"478","key":"10.1016\/j.cellsig.2026.112885_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5758","article-title":"Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer","volume":"11","author":"Watt","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.cellsig.2026.112885_bb0105","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1158\/0008-5472.CAN-21-3822","article-title":"Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer","volume":"82","author":"Shangguan","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112885_bb0110","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.2147\/OTT.S315813","article-title":"SQLE mediates metabolic reprogramming to promote LN metastasis in castration-resistant prostate cancer","volume":"14","author":"Xu","year":"2021","journal-title":"Onco. Targets Ther."},{"issue":"16","key":"10.1016\/j.cellsig.2026.112885_bb0115","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.7150\/thno.58655","article-title":"GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy","volume":"11","author":"Mukha","year":"2021","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.cellsig.2026.112885_bb0120","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012748118","article-title":"A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer","volume":"118","author":"Xu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0125","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41388-021-02155-z","article-title":"Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer","volume":"41","author":"Xu","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","article-title":"Targeting glutamine metabolism as a potential target for cancer treatment","volume":"44","author":"Zou","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.cellsig.2026.112885_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162871","article-title":"Glutamine metabolism and prostate cancer","volume":"16","author":"Erb","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.5665","article-title":"Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth","volume":"254","author":"Wang","year":"2021","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112885_bb0145","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1021\/acs.molpharmaceut.5c00341","article-title":"Targeted metabolic alterations in prostate cancer: a promising therapeutic strategy","volume":"22","author":"Qu","year":"2025","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021391","article-title":"Alteration of lipid metabolism in prostate cancer: multifaceted oncologic implications","volume":"24","author":"Zekovic","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112885_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41419-024-06893-2","article-title":"Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancer","volume":"15","author":"Bidgood","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0160","first-page":"192","article-title":"The role of glutamine metabolism in castration-resistant prostate cancer","volume":"25","author":"Zhao","year":"2023","journal-title":"Asian J. Androl."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0165","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1038\/s41598-023-40347-7","article-title":"Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression","volume":"13","author":"Lazniewska","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0170","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/ERC-17-0051","article-title":"GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling","volume":"25","author":"White","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.cellsig.2026.112885_bb0175","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54166","article-title":"Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis","volume":"9","author":"Nassar","year":"2020","journal-title":"Elife"},{"issue":"24","key":"10.1016\/j.cellsig.2026.112885_bb0180","doi-asserted-by":"crossref","first-page":"12975","DOI":"10.1073\/pnas.94.24.12975","article-title":"Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins","volume":"94","author":"Swinnen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112885_bb0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112885_bb0190","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1158\/1541-7786.MCR-17-0410","article-title":"SREBF1 activity is regulated by an AR\/mTOR nuclear axis in prostate cancer","volume":"16","author":"Audet-Walsh","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0195","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1541-7786.MCR-16-0480","article-title":"Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer","volume":"15","author":"White","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112885_bb0200","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13402-020-00575-9","article-title":"Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5alpha-dihydrotestosterone regulation","volume":"44","author":"Cardoso","year":"2021","journal-title":"Cell. Oncol. (Dordr)"},{"issue":"S4","key":"10.1016\/j.cellsig.2026.112885_bb0205","first-page":"1","article-title":"Cholesterol triggers nuclear co-association of androgen receptor, p160 steroid coactivators, and p300\/CBP-associated factor leading to androgenic axis transactivation in castration-resistant prostate cancer","volume":"56","author":"Pimenta","year":"2022","journal-title":"Cell. Physiol. Biochem."},{"issue":"23","key":"10.1016\/j.cellsig.2026.112885_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235900","article-title":"Acetyl-CoA counteracts the inhibitory effect of antiandrogens on androgen receptor signaling in prostate cancer cells","volume":"14","author":"Makhov","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0215","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/1541-7786.MCR-20-0379","article-title":"Long-chain acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer","volume":"19","author":"Ma","year":"2021","journal-title":"Mol. Cancer Res."},{"issue":"49","key":"10.1016\/j.cellsig.2026.112885_bb0220","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1038\/onc.2016.171","article-title":"Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth","volume":"35","author":"Obinata","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0225","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/1541-7786.MCR-17-0458","article-title":"Targeted AKT inhibition in prostate cancer cells and spheroids reduces aerobic glycolysis and generation of hyperpolarized [1-(13)C] lactate","volume":"16","author":"Tee","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"16","key":"10.1016\/j.cellsig.2026.112885_bb0230","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-21-4272","article-title":"The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer","volume":"28","author":"Chakraborty","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112885_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153851","article-title":"Molecular landscape of c-Myc signaling in prostate cancer: a roadmap to clinical translation","volume":"233","author":"Faskhoudi","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.111001","article-title":"Triglyceride lipase PNPLA2-independent suppression of c-MYC signaling by the metabolic coactivator ABHD5 in prostate cancer","volume":"302","author":"Lotvola","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.cellsig.2026.112885_bb0245","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-16-0124","article-title":"The dual inhibition of RNA pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer","volume":"22","author":"Rebello","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112396","article-title":"AMPK activation protects against prostate cancer by inducing a catabolic cellular state","volume":"42","author":"Penfold","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2026.112885_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216657","article-title":"Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer","volume":"587","author":"Zhao","year":"2024","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112885_bb0260","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/0008-5472.CAN-21-0914","article-title":"Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer","volume":"82","author":"Ippolito","year":"2022","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0265","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1038\/s44319-024-00180-z","article-title":"Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer","volume":"25","author":"Ippolito","year":"2024","journal-title":"EMBO Rep."},{"issue":"27","key":"10.1016\/j.cellsig.2026.112885_bb0270","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41388-019-0805-7","article-title":"Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer","volume":"38","author":"Ippolito","year":"2019","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.cellsig.2026.112885_bb0275","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/s41388-019-0688-7","article-title":"Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8\/miR21 axis","volume":"38","author":"Comito","year":"2019","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0280","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4103\/aja.aja_47_19","article-title":"Role of tumor-associated immune cells in prostate cancer: angel or devil?","volume":"21","author":"Wu","year":"2019","journal-title":"Asian J. Androl."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0285","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1061186X.2024.2418344","article-title":"Interactions and communications in the prostate tumour microenvironment: evolving towards effective cancer therapy","volume":"33","author":"Dai","year":"2025","journal-title":"J. Drug Target."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112885_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/biom15060826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"issue":"19","key":"10.1016\/j.cellsig.2026.112885_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194757","article-title":"Overcoming immune resistance in prostate cancer: challenges and advances","volume":"13","author":"Movassaghi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6024","key":"10.1016\/j.cellsig.2026.112885_bb0305","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.cellsig.2026.112885_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133473","article-title":"Lactate as key metabolite in prostate cancer progression: what are the clinical implications?","volume":"15","author":"Chetta","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0315","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12964-019-0434-3","article-title":"CXCL1-LCN2 paracrine axis promotes progression of prostate cancer via the Src activation and epithelial-mesenchymal transition","volume":"17","author":"Lu","year":"2019","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0320","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12935-021-02126-0","article-title":"TACR2 is associated with the immune microenvironment and inhibits migration and proliferation via the Wnt\/beta-catenin signaling pathway in prostate cancer","volume":"21","author":"Jianfeng","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/03915603221111125","article-title":"Role of monocarboxylate transporters and glucose transporters in prostate cancer","volume":"90","author":"Vovdenko","year":"2023","journal-title":"Urologia"},{"key":"10.1016\/j.cellsig.2026.112885_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.01.007","article-title":"Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics?","volume":"90","author":"Singh","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.cellsig.2026.112885_bb0335","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/CMAR.S421771","article-title":"Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment","volume":"15","author":"Liu","year":"2023","journal-title":"Cancer Manag. Res."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112885_bb0340","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/14728222.2023.2248381","article-title":"Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence","volume":"27","author":"Zohar","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.cellsig.2026.112885_bb0345","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217209","article-title":"Hypoxia-inducible factor 1A inhibition overcomes castration resistance of prostate tumors","volume":"15","author":"Terzic","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112885_bb0350","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1124\/mol.114.097477","article-title":"Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells","volume":"87","author":"Fernandez","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0355","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cellsig.2026.112885_bb0360","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","article-title":"Immunosuppressive activities of adenosine in cancer","volume":"29","author":"Allard","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112885_bb0365","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1535-7163.MCT-22-0721","article-title":"Arginase 1\/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy","volume":"22","author":"Borek","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0370","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12885-023-10539-5","article-title":"Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms","volume":"23","author":"Nozawa","year":"2023","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112885_bb0375","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/acsptsci.4c00448","article-title":"Cannabidiol suppresses metastatic castration-resistant prostate cancer progression and recurrence through modulating tryptophan catabolism","volume":"7","author":"Mudhish","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0380","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12916-022-02457-3","article-title":"The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell\u2019s metabolic crosstalk","volume":"20","author":"Altuna-Coy","year":"2022","journal-title":"BMC Med."},{"issue":"1.2","key":"10.1016\/j.cellsig.2026.112885_bb0385","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2152\/jmi.65.9","article-title":"Adipose tissue: critical contributor to the development of prostate cancer","volume":"65","author":"Uehara","year":"2018","journal-title":"J. Med. Investig."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0390","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/ijc.28903","article-title":"Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression","volume":"135","author":"Uehara","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0395","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3892\/ol.2023.13749","article-title":"Prostate cancer bone metastases biology and clinical management (review)","volume":"25","author":"Archer Goode","year":"2023","journal-title":"Oncol. Lett."},{"issue":"23","key":"10.1016\/j.cellsig.2026.112885_bb0400","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1038\/s41388-019-0736-3","article-title":"Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion","volume":"38","author":"Wang","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13046-023-02610-7","article-title":"Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer","volume":"42","author":"Kong","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112885_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104910","article-title":"Targeting cancer metabolism: therapeutic potential of the fatty acid synthase (FASN) inhibitors","volume":"214","author":"Nuzzo","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0415","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/path.5587","article-title":"Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss","volume":"253","author":"Bastos","year":"2021","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0420","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/pros.24654","article-title":"Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer","volume":"84","author":"Moon","year":"2024","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0425","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12964-025-02344-3","article-title":"Disruption of glutamine transport uncouples the NUPR1 stress-adaptation program and induces prostate cancer radiosensitivity","volume":"23","author":"Kahya","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"10","key":"10.1016\/j.cellsig.2026.112885_bb0430","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41419-023-06203-2","article-title":"Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"issue":"13","key":"10.1016\/j.cellsig.2026.112885_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25136939","article-title":"Mitochondrial elongation and ROS-mediated apoptosis in prostate cancer cells under therapy with apalutamide and complex I inhibitor","volume":"25","author":"Baumgartner","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cellsig.2026.112885_bb0440","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1535-7163.MCT-23-0540","article-title":"A compound that inhibits glycolysis in prostate cancer controls growth of advanced prostate cancer","volume":"23","author":"Uo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.cellsig.2026.112885_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217522","article-title":"Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer","volume":"616","author":"Subramaniam","year":"2025","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.cellsig.2026.112885_bb0450","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235612","article-title":"Targeting metabolic vulnerabilities to overcome prostate cancer resistance: dual therapy with apalutamide and complex I inhibition","volume":"15","author":"Baumgartner","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2026.112885_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177300","article-title":"Lactoferrin conjugated radicicol nanoparticles enhanced drug delivery and cytotoxicity in prostate cancer cells","volume":"991","author":"Kooshan","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"26","key":"10.1016\/j.cellsig.2026.112885_bb0460","doi-asserted-by":"crossref","first-page":"40621","DOI":"10.18632\/oncotarget.9746","article-title":"Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0465","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/cam4.1410","article-title":"Oxaloacetate induces apoptosis in HepG2 cells via inhibition of glycolysis","volume":"7","author":"Kuang","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.cellsig.2026.112885_bb0470","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.redox.2018.05.014","article-title":"Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells","volume":"18","author":"Jose","year":"2018","journal-title":"Redox Biol."},{"key":"10.1016\/j.cellsig.2026.112885_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.963066","article-title":"Identification and characterization of a novel SNAT2 (SLC38A2) inhibitor reveals synergy with glucose transport inhibition in cancer cells","volume":"13","author":"Gauthier-Coles","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0480","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0485","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.7150\/ijbs.99716","article-title":"Tumor ABCC4-mediated release of PGE2 induces CD8(+) T cell dysfunction and impairs PD-1 blockade in prostate cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0490","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41420-025-02774-5","article-title":"Targeting endoplasmic reticulum stress and nitroso-redox imbalance in neuroendocrine prostate cancer: the therapeutic role of nitric oxide","volume":"11","author":"Firdaus","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.cellsig.2026.112885_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113775","article-title":"Metal-phenolic networks reverse the immunosuppressive tumor microenvironment via dual metabolism regulation and immunogenic cell death","volume":"383","author":"Nam","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.cellsig.2026.112885_bb0500","article-title":"Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization","volume":"14","author":"Katopodi","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112885_bb0505","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112885_bb0510","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0515","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s42255-023-00963-z","article-title":"Metabolic heterogeneity in cancer","volume":"6","author":"Demicco","year":"2024","journal-title":"Nat. Metab."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0520","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1158\/1541-7786.MCR-22-0796","article-title":"Multi-substrate metabolic tracing reveals marked heterogeneity and dependency on fatty acid metabolism in human prostate cancer","volume":"21","author":"Fidelito","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0525","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/COC.0000000000001215","article-title":"Metabolic plasticity in prostate cancer: the Warburg effect and its clinical relevance","volume":"48","author":"Sabbah","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0530","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00120-023-02222-1","article-title":"Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review","volume":"63","author":"Klemm","year":"2024","journal-title":"Urologie"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112885_bb0535","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2024.07.013","article-title":"Systemic treatments for metastatic prostate cancer in 2024","volume":"10","author":"Gizzi","year":"2024","journal-title":"Eur. Urol. Focus"},{"issue":"26","key":"10.1016\/j.cellsig.2026.112885_bb0540","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.cellsig.2026.112885_bb0545","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10398","key":"10.1016\/j.cellsig.2026.112885_bb0550","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.cellsig.2026.112885_bb0555","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10276","key":"10.1016\/j.cellsig.2026.112885_bb0560","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112885_bb0565","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0570","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112885_bb0575","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0580","first-page":"2856","article-title":"Effect of PTEN loss on metabolic reprogramming in prostate cancer cells","volume":"17","author":"Zhou","year":"2019","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112885_bb0585","doi-asserted-by":"crossref","first-page":"2","DOI":"10.31083\/j.fbe1501002","article-title":"Targeting glutamine metabolism in prostate cancer","volume":"15","author":"Bhowmick","year":"2023","journal-title":"Front. Biosci. (Elite Ed.)"},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0590","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112885_bb0595","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00432-022-04113-y","article-title":"Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis","volume":"149","author":"Krishnan","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112885_bb0600","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41418-024-01295-5","article-title":"Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.cellsig.2026.112885_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101466","article-title":"Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC)","volume":"59","author":"Xu","year":"2022","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0610","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/0008-5472.CAN-23-0519","article-title":"Obesogenic high-fat diet and MYC cooperate to promote lactate accumulation and tumor microenvironment Remodeling in prostate cancer","volume":"84","author":"Boufaied","year":"2024","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112885_bb0615","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111590","article-title":"Druggable metabolic vulnerabilities are exposed and masked during progression to castration resistant prostate cancer","volume":"12","author":"Choi","year":"2022","journal-title":"Biomolecules"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:41:24Z","timestamp":1789753284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826005449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":123,"alternative-id":["S0898656826005449"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112885","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic plasticity in castration-resistant prostate cancer: reprogramming mechanisms and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112885"}}